Blog Syngene Contact Us    Quick links
About Biocon Our Business Research & Development Biocon's Technology Investors Media Careers CSR
Biocon Quarterly Results
  > INVESTORS
  Overview
  Corporate Structure
  Corporate Governance
  Company History
  Annual General Meeting
  Postal Ballot
  Investor FAQs
  Stock Info
  Financial Results
  Subsidiary Financials
  Annual Report
  Disclosure to Stock Exchange
  Nomination form
  Press Releases
  Presentations
  Analyst Coverage
  Investor Contacts
  
  
     
 
Financials

Financial Results

 
 
 
  FY 18-19 Q1 H1 9M FY
  Notice Ad Biocon_Q1 FY18_Press Release Biocon_Q2 FY18_Press Release
  Press Release Biocon_Q1 FY18_Press Release Biocon_Q2 FY18_Press Release Biocon_Q3 FY19_Press Release Biocon_Q3 FY19_Press Release
  Fact Sheet Biocon_Q1 FY18_Press Release Biocon_Q2 FY18_Press Release Biocon_Q3 FY19_Press Release Biocon_Q3 FY19_Press Release
  Transcript of the Call Biocon_Q1FY18_CallTranscript Biocon_Q2FY18_Call_Transcript Biocon_Q3FY19_Call_Transcript Biocon_Q4FY19_Call_Transcript
  Newspaper Advertisement Biocon_Q1 FY18_Press Release Biocon_Q2 FY19_Press Release Biocon_Q3 FY19_Press Release Q3-18-Signed-LR-&-Results
  Results Biocon_Q1 FY18_Press Release Biocon_Q2 FY18_Press Release Biocon_Q3 FY19_Press Release
  Investor Presentation Investor Presentation Investor Presentation Investor Presentation FY Investor Presentation

FINANCIAL HIGHLIGHTS (CONSOLIDATED): Q3FY19

Particulars 

Q3FY19

Q3FY18

Growth

INCOME

Small Molecules 469 369 27%
Biologics

449 190 136%
Branded Formulations 212 156 36%
Research Services 467 388 20%
Inter-segment -56 -45 26%
Revenue from Operations# 1,541 1,058 46%
Other Income 25 34 -24%
TOTAL REVENUE 1,566 1,092 43%
EBITDA 406 256 59%
PBT 289 150 93%
Net Profit 217 92 136%
Exceptional item (net of tax) 6

-

Net Profit (adjusted for exceptional item) 211 92 130%
R&D Expenses in P&L 77 53 45%
Gross R&D Spends 106 94 12%
EBITDA Margin 26% 23%

Core EBITDA Margin 32% 27%

Net Profit Margin* 14% 8%

#includes Licensing Income 7 12

Year 2017-18 Financial Highlights

In Rs. Crore 
  FY 17-18 Q1 H1 9M FY
  Revenue 988 1019 1092 1237
  EBITDA 246 233 256 300
  Net Profit 81 69 92 130
  R&D Expenses in P&L 58 54 53 51
  Total R&D Spends 96 93 94 98
  EBITDA Margins 25% 23% 23% 24%
  Core EBITDA Margin 29% 27% 27% 26%
  Net Profit Margins 8% 7% 8% 11%
 
  * As per the new accounting standard: Ind-AS  
  FY16-17  FY16-17  FY16-17  FY15-16  FY15-16  FY14-15  FY13-14  FY12-13  FY11-12  FY10-11  FY09-10  FY08-09  FY07-08  FY06-07  FY05-06  FY04-05 

 
Quarterly Results
 FY20-21
 FY19-20
 FY18-19
 FY17-18
 FY16-17
 FY15-16
 FY14-15
 FY13-14
 FY12-13
 FY11-12
 FY10-11
 FY09-10
 FY08-09
 FY07-08
 FY06-07
 FY05-06
 FY04-05
 
 
     
  Biocon

Businesses

 Recommended sites Biocon on  
  Home
About Us
Investor Relations
Media Relations
Careers
Site Map
Contact Us 		Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

 ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved